Clinical Trials Logo

Clinical Trial Summary

This research study is being done to estimate the safety and efficacy of zandelisib and tazemetostat in people with relapsed or refractory follicular lymphoma (FL) This research study involves Zandelisib in combination with Tazemetostat. MEI Pharma, Inc, a biotechnology company, is supporting this research study by providing funding for the research study, including the study drug zandelisib.


Clinical Trial Description

This is a phase 1 study of Zandelisib and Tazemetostat with a phase 2 expansion two-arm component in patients with relapsed or refractory follicular lymphoma (FL) grade 1-3A. - This research study involves Zandelisib in combination with Tazemetostat. This is the first time the drug combination of Zandelisib and Tazemetostat will be given to humans. - The research study procedures include screening for eligibility and study treatment including evaluations and follow up visits - Participants will receive study treatment as long as treatment is tolerated and the disease does not worsen. - The maximum length of time on the study drug combination is 14 months. Participants will followed for up to 2 years. - It is expected that about 34 people will take part in this research study. The U.S. Food and Drug Administration (FDA) has not approved zandelisib as a treatment for any disease. The U.S. FDA has approved tazemetostat as a treatment for relapsed or refractory follicular lymphoma as a single therapy. This is the first time this drug combination will be given to humans. This is a Phase I/II clinical trial. Participants will be asked to participate in either the Phase I part or Phase II part of this clinical trial. - A Phase I clinical trial tests the safety of an investigational drug and also tries to define the appropriate dose of the investigational drug to use for further studies. - A Phase II clinical trials test the safety and effectiveness of an investigational drug to learn whether the drug works in treating a specific disease. "Investigational" means that the drug is being studied. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05604417
Study type Interventional
Source Massachusetts General Hospital
Contact
Status Withdrawn
Phase Phase 1/Phase 2
Start date January 2023
Completion date December 1, 2026

See also
  Status Clinical Trial Phase
Recruiting NCT05848765 - Relapsed Follicular Lymphoma Randomised Trial Against Standard ChemoTherapy Phase 2
Withdrawn NCT04635683 - Lenalidomide, Umbralisib, and Ublituximab for the Treatment of Relapsed or Refractory Indolent Non-Hodgkin Lymphoma or Mantle Cell Lymphoma Phase 1
Active, not recruiting NCT01955499 - Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma Phase 1
Not yet recruiting NCT06068881 - A Study to Assess Efficacy and Safety of Oral Tazemetostat in Adult Participants With Relapsed/Refractory Follicular Lymphoma That Does Not Have an "EZH2 Gain-of-function" Genetic Mutation Phase 2
Active, not recruiting NCT03583424 - Venetoclax, Carmustine, Etoposide, Cytarabine, and Melphalan Before Stem Cell Transplant in Treating Participants With Relapsed or Refractory Non-Hodgkin Lymphoma Phase 1/Phase 2
Recruiting NCT04007029 - Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic Leukemia Phase 1
Withdrawn NCT03579927 - CAR.CD19-CD28-zeta-2A-iCasp9-IL15-Transduced Cord Blood NK Cells, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Participants With B-cell Lymphoma Phase 1/Phase 2
Active, not recruiting NCT04578600 - CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymphoma Phase 1
Recruiting NCT04447716 - An Early Phase Study of Venetoclax, Lenalidomide, and Rituximab/Hyaluronidase in Slow-Growing Lymphomas That Have Come Back After Treatment or Have Not Responded to Treatment Phase 1
Recruiting NCT05025800 - ALX148, Rituximab and Lenalidomide for the Treatment of Indolent and Aggressive B-cell Non-Hodgkin Lymphoma Phase 1/Phase 2
Completed NCT03019640 - Umbilical Cord Blood NK Cells, Rituximab, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Patients With Recurrent or Refractory B-Cell Non-Hodgkin's Lymphoma Phase 2
Completed NCT02927964 - TLR9 Agonist SD-101, Ibrutinib, and Radiation Therapy in Treating Patients With Relapsed or Refractory Grade 1-3A Follicular Lymphoma Phase 1/Phase 2
Terminated NCT04699461 - Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine Versus Idelalisib in Participants With Relapsed or Refractory Follicular Lymphoma Phase 2
Completed NCT02869633 - Ibrutinib in Treating Patients With Refractory or Relapsed Lymphoma After Donor Stem Cell Transplant Phase 2
Active, not recruiting NCT02568553 - Lenalidomide and Blinatumomab for the Treatment of Relapsed Non-Hodgkin Lymphoma Phase 1
Completed NCT01995669 - Lenalidomide and Obinutuzumab in Treating Patients With Relapsed Indolent Non-Hodgkin Lymphoma Phase 1/Phase 2
Withdrawn NCT05152459 - Tazemetostat in Combination With Umbralisib and Ublituximab for the Treatment Relapsed or Refractory Follicular Lymphoma Phase 1/Phase 2
Active, not recruiting NCT03401853 - Pembrolizumab With Rituximab or Obinutuzumab in Treating Patients With Relapsed or Refractory Follicular Lymphoma or Diffuse Large B Cell Lymphoma Phase 2
Active, not recruiting NCT03479268 - Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin Lymphoma Phase 1
Recruiting NCT06191887 - B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic Malignancies Phase 1